PBA
ABVX

Paradigm Biocapital Advisors’s Abivax ABVX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86M Sell
772,473
-645,000
-46% -$76.3M 1.76% 18
2025
Q4 		$191M Sell
1,417,473
-146,723
-9% -$16M 4.88% 6
2025
Q3 		$133M Buy
+1,564,196
New +$95.9M 3.78% 7

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Paradigm Biocapital Advisors's ABVX Position: Q1 2026 in Review

Paradigm Biocapital Advisors reduced its Abivax (ABVX) stake by 46% in Q1 2026, selling an estimated $76.3M and leaving 772,473 shares worth $86M. The position accounts for 1.76% of the portfolio, ranked #18.

Paradigm Biocapital Advisors first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $191M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Paradigm Biocapital Advisors held 772,473 shares of Abivax worth $86M as of Q1 2026.
  • Paradigm Biocapital Advisors sold 645,000 Abivax shares in Q1 2026, an estimated $76.3M.
  • Abivax made up 1.76% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #18 holding.
  • Paradigm Biocapital Advisors first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • Paradigm Biocapital Advisors's Abivax position peaked at $191M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.